Table 1

Summary of key drug-drug interactions between HIV drugs and the licensed DAAs and dosing recommendations
Telaprevir Boceprevir
ATV/r Monitoring for hyperbilirubinemia recommended Consider on a case by case basis if deemed necessary
DRV/r/, FPV/r LPV/r Not recommended Not recommended
EFV Increase TVR to 1,250 mg q8h Not recommended
ETR No dose adjustment needed No dose adjustment needed
RPV No dose adjustment needed No dose adjustment needed
RAL No dose adjustment needed No dose adjustment needed
TDF Increased monitoring is warranted No dose adjustment needed

Rockstroh and Bhagani

Rockstroh and Bhagani BMC Medicine 2013 11:234   doi:10.1186/1741-7015-11-234

Open Data